Targeting angiogenesis in pancreatic cancer.
Philip
Philip A
PA
Karmanos Cancer Center, Detroit, MI 48201, USA. philipp@karmanos.org
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000077784:Axitinib; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D007191:Indazoles / Q000494:pharmacology / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D016032:Randomized Controlled Trials as Topic; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors*; D000093542:Gemcitabine
D020533:Angiogenesis Inhibitors; D004791:Enzyme Inhibitors; D007093:Imidazoles; D007191:Indazoles; D003841:Deoxycytidine; D000077784:Axitinib; D011505:Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor; D000093542:Gemcitabine